NCT05331729已完成1 期
Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis - a Non-randomized Proof-of-concept Study Comparing Patients with Idiopathic Pulmonary Fibrosis and Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Lung SUVmean of 18F-FMISO measured in PET
研究概览
简要总结
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, lethal disease of unknown etiology and with a variable course. There is currently no test in routine care that can assess both the anatomical and functional damage of the disease at an early stage. This is the first human study in IPF to evaluate the value of a non-invasive tracer, 18F-fluoromisonidazole (18F-FMISO), targeting hypoxia in IPF patients.
This is a Phase I, proof-of-concept, single-center, open-label, parallel group study.
It will include 2 groups:
- 1 group of 10 IPF patients
- 1 group of 10 healthy volunteers matched to IPF patients for age and gender
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For all patients (IPF and healthy volunteers) :
- •Person who has given written consent
- •Age ≥ 50 years
- •Absence of disease, comorbidity, or treatment that may interfere with the evaluation of the study objective, as decided by the investigator
- •For patients with IPF only:
- •Diagnosis of IPF according to the criteria of the current international recommendations (ATS/ERS/JRS/ALAT of 2011) and validated in a multi-disciplinary meeting in a Competence or Reference Center
- •Patients who have had a high-resolution thoracic CT scan less than 1 month previously as part of the management of their disease
- •Patients who have had a PFT less than 1 month previously as part of the management of their disease
- •For healthy volunteers only:
- •Absence of functional respiratory signs - absence of dyspnea on exertion and at rest and absence of chronic cough.
- •Normal clinical examination with no crackles on pulmonary auscultation
- •No personal history of chronic hypoxemic respiratory disease
排除标准
- •Person who is not covered by national health insurance
- •Cancer or history of cancer in the past 5 years (except basal cell skin cancer)
- •Chronic lung disease other than IPF or a history incompatible with the diagnosis of idiopathic pulmonary fibrosis (thoracic radiotherapy, pneumotoxic chemotherapy, etc.)
- •Exacerbation of IPF during treatment
- •Active smoking
- •Patient requiring long-term oxygen therapy (excluding ambulatory oxygen therapy alone)
- •Contraindication to PET or CT scan or presence of a condition disturbing the interpretation :
- •known allergy to 18F-FMISO
- •pregnancy or breastfeeding
- •claustrophobia
- •uncontrolled type I/II diabetes (HbA1c >7%)
- •surgical intervention in the previous month
- •Radiotherapy session in the previous 3 months
- •concomitant granulomatous condition (sarcoidosis type) or pulmonary inflammation
- •Moderate or severe renal insufficiency (GFR < 70 ml/min/1.73 m²)
- •Person under legal protection (curatorship, guardianship)
- •Adult unable to express consent
- •SECONDARY EXCLUSION CRITERIA only for healthy volunteers
- •Abnormal 6 min walk test at screening
- •Abnormal PFT at screening with FVC ≤ 80% of predicted value and DLCO ≤ 75% of predicted value
结局指标
主要结局
Lung SUVmean of 18F-FMISO measured in PET
时间窗: At baseline
Comparison in IPF patients and healthy volunteers
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving PirfenidoneIdiopathic Pulmonary FibrosisNCT03692481Assistance Publique - Hôpitaux de Paris50
终止
2 期
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPFPersistent Cough in IPFChronic CoughIPFNCT03864328Respivant Sciences GmbH108
Unknown
不适用
Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPFIdiopathic Pulmonary FibrosisNCT03360032University Hospitals Coventry and Warwickshire NHS Trust43
招募中
1 期
Dose-Escalation Study of Artesunate Patients With IPFIdiopathic Pulmonary FibrosisNCT05988463Joseph C. Wu15
Unknown
不适用
Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)Interstitial Lung DiseasesNCT02509364Shanghai Pulmonary Hospital, Shanghai, China300